Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Change in Account Payables (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Change in Account Payables for 12 consecutive years, with -$1.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables fell 263.53% year-over-year to -$1.9 million, compared with a TTM value of -$1.3 million through Sep 2025, down 230.69%, and an annual FY2024 reading of -$163000.0, up 93.31% over the prior year.
  • Change in Account Payables was -$1.9 million for Q3 2025 at Avalo Therapeutics, down from $1.7 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $9.3 million in Q1 2021 and bottomed at -$9.7 million in Q2 2021.
  • Average Change in Account Payables over 5 years is -$110473.7, with a median of $37000.0 recorded in 2023.
  • Peak annual rise in Change in Account Payables hit 3620.72% in 2021, while the deepest fall reached 5651.79% in 2021.
  • Year by year, Change in Account Payables stood at -$198000.0 in 2021, then skyrocketed by 824.75% to $1.4 million in 2022, then tumbled by 123.83% to -$342000.0 in 2023, then plummeted by 346.78% to -$1.5 million in 2024, then dropped by 23.82% to -$1.9 million in 2025.
  • Business Quant data shows Change in Account Payables for AVTX at -$1.9 million in Q3 2025, $1.7 million in Q2 2025, and $398000.0 in Q1 2025.